Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BCA101

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Biocon

Drug class:

EGFR inhibitor, TGFβ inhibitor

Related drugs:

‹

befotertinib (1)

luspatercept-aamt (5)

cetuximab (317)

osimertinib (240)

erlotinib (229)

gefitinib (183)

panitumumab (114)

lapatinib (105)

neratinib (102)

brigatinib (45)

aumolertinib (22)

amivantamab-vmjw (15)

furmonertinib (8)

mobocertinib (7)

tarloxotinib bromide (7)

nimotuzumab (5)

rociletinib (5)

tomuzotuximab (4)

necitumumab (2)

ABP 494 (cetuximab biosimilar) (1)

Compound 6a (1)

abivertinib (1)

befotertinib (1)

luspatercept-aamt (5)

›

EGFR amplification	Lung Non-Small Cell Squamous Cancer	EGFR amplification	Lung Non-Small Cell Squamous Cancer	BCA101 Sensitive: C3 – Early Trials AACR 2023 - 1 week (New C3) BCA101 Sensitive : C3 AACR 2023 - 1wk	BCA101 Sensitive: C3 – Early Trials AACR 2023 - 1 week BCA101 Sensitive : C3 AACR 2023 - 1 week - (New C3)
EGFR expression	Solid Tumor	EGFR expression	Solid Tumor	BCA101 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) BCA101 Sensitive : D AACR 2023 - 1wk	BCA101 Sensitive: D – Preclinical AACR 2023 - 1 week BCA101 Sensitive : D AACR 2023 - 1 week - (New D)